A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque...
Plaque PsoriasisPsoriatic ArthritisThe main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
Psoriatic ArthritisThis is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable...
Autoimmune DiseaseCrohn Disease12 moreThis phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic...
ArthritisPsoriaticThe purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Diet Interventions in Psoriatic Arthritis
Psoriatic ArthritisThe purpose of this study is to learn whether changing diet impacts psoriatic arthritis (PsA).
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants...
Psoriatic ArthritisThe purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Psoriatic ArthritisThe trial is a double-blinded randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
Psoriatic ArthritisThe objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study will include 16 weeks of treatment, 36 weeks of LTE, and a 30-day follow-up period.
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis...
ArthritisJuvenileThe purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile...
Behçet's DiseaseJuvenile Psoriatic ArthritisThe primary objective of this study is to evaluate the long-term safety of apremilast in participants 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.